Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

High Dose of Pfizer’s Xeljanz Raises Red Flag in a Post-Marketing Study

Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz has been a strong performer for the company, bringing in $1.77 billion in revenue last year, but now the company has indicated it intends to make a change in a post-marketing study due to safety concerns.

Read More »

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc. – rebuked by U.S. Senator Bernie Sanders for high drug prices – defended the company’s $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Read More »

U.S. health spending to rise 5.5 percent per year over next decade: CMS

U.S. health spending is expected to grow at an average rate of 5.5 percent yearly from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare.

Read More »

Indivior launches generic version of own opioid drug

Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.

Read More »

U.S. top court rejects bid to block Indivior opioid drug copycat

The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm’s lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy’s Laboratories Ltd.

Read More »

U.S. top court rejects Maryland bid to revive drug price-gouging law

The U.S. Supreme Court rejected Maryland’s bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs.

Read More »

Keytruda In Combination With Inlyta Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced RCC

Merck & Co. announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating the company’s anti-PD-1 therapy Keytruda in combination with Inlyta, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma (RCC) at the 2019 Genitourinary Cancers Symposium.

Read More »

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.

Read More »

Antipsychotic Rexulti Fails Two Bipolar Phase III Trials

Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that the antipsychotic drug Rexulti (brexpiprazole) failed to meet the primary endpoint in two Phase III clinical studies to treat manic episodes in patients with bipolar I disorder.

Read More »

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom